| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Biology and Biocalorimetry Center, Johns Hopkins University, Baltimore, Maryland 21218, USA
Reprint requests to: Dr. Ernesto Freire, Department of Biology and Biocalorimetry Center, Johns Hopkins University, Baltimore, MD 21218, USA; e-mail: ef{at}jhu.edu; fax: (410) 516-6469.
Amprenavir is one of six protease inhibitors presently approved for clinical use in the therapeutic treatment of AIDS. Biochemical and clinical studies have shown that, unlike other inhibitors, Amprenavir is severely affected by the protease mutation I50V, located in the flap region of the enzyme. TMC-126 is a second-generation inhibitor, chemically related to Amprenavir, with a reported extremely low susceptibility to existing resistant mutations including I50V. In this paper, we have studied the thermodynamic and molecular origin of the response of these two inhibitors to the I50V mutation and the double active-site mutation V82F/I84V that affects all existing clinical inhibitors. Amprenavir binds to the wild-type HIV-1 protease with high affinity (5.0 x 109 M-1 or 200 pM) in a process equally favored by enthalpic and entropic contributions. The mutations I50V and V82F/I84V lower the binding affinity of Amprenavir by a factor of 147 and 104, respectively. TMC-126, on the other hand, binds to the wild-type protease with extremely high binding affinity (2.6 x 1011 M-1 or 3.9 pM) in a process in which enthalpic contributions overpower entropic contributions by almost a factor of 4. The mutations I50V and V82F/I84V lower the binding affinity of TMC-126 by only a factor of 16 and 11, respectively, indicating that the binding affinity of TMC-126 to the drug-resistant mutants is still higher than the affinity of Amprenavir to the wild-type protease. Analysis of the data for TMC-126 and KNI-764, another second-generation inhibitor, indicates that their low susceptibility to mutations is caused by their ability to compensate for the loss of interactions with the mutated target by a more favorable entropy of binding.
Keywords: HIV-1 protease; drug resistance; HIV-1 protease inhibitors; isothermal titration calorimetry; Amprenavir; TMC-126
Abbreviations: HIV, human immunodeficiency virus • IPTG, isopropyl-ß-D-thiogalactoside • MES, 2-(N-morpholino)ethanesulfonic acid • ACES, N-(2-acetamido)-2-aminoethanesulfonic acid • EDTA, (ethylenedinitrile)tetraacetic acid • DMSO, dimethyl sulfoxide • ME, 2-mercaptoethanol • Tris, tris(hydroxymethyl)aminoethane • Gly-Gly, glycylglycine • ITC, isothermal titration calorimetry
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Muzammil, A. A. Armstrong, L. W. Kang, A. Jakalian, P. R. Bonneau, V. Schmelmer, L. M. Amzel, and E. Freire Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance Mutations J. Virol., May 15, 2007; 81(10): 5144 - 5154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Foulkes, M. Prabu-Jeyabalan, D. Cooper, G. J. Henderson, J. Harris, R. Swanstrom, and C. A. Schiffer Role of Invariant Thr80 in Human Immunodeficiency Virus Type 1 Protease Structure, Function, and Viral Infectivity J. Virol., July 15, 2006; 80(14): 6906 - 6916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Muralidhara, S. Negi, C. C. Chin, W. Braun, and J. R. Halpert Conformational Flexibility of Mammalian Cytochrome P450 2B4 in Binding Imidazole Inhibitors with Different Ring Chemistry and Side Chains: SOLUTION THERMODYNAMICS AND MOLECULAR MODELING J. Biol. Chem., March 24, 2006; 281(12): 8051 - 8061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yanchunas Jr., D. R. Langley, L. Tao, R. E. Rose, J. Friborg, R. J. Colonno, and M. L. Doyle Molecular Basis for Increased Susceptibility of Isolates with Atazanavir Resistance-Conferring Substitution I50L to Other Protease Inhibitors Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3825 - 3832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. King, M. Prabu-Jeyabalan, E. A. Nalivaika, P. Wigerinck, M.-P. de Bethune, and C. A. Schiffer Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor J. Virol., November 1, 2004; 78(21): 12012 - 12021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Locatelli, G. Campiani, R. Cancio, E. Morelli, A. Ramunno, S. Gemma, U. Hubscher, S. Spadari, and G. Maga Effects of Drug Resistance Mutations L100I and V106A on the Binding of Pyrrolobenzoxazepinone Nonnucleoside Inhibitors to the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Catalytic Complex Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1570 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Perryman, J.-H. Lin, and J. A. McCammon HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: Possible contributions to drug resistance and a potential new target site for drugs Protein Sci., April 1, 2004; 13(4): 1108 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Logsdon, J. F. Vickrey, P. Martin, G. Proteasa, J. I. Koepke, S. R. Terlecky, Z. Wawrzak, M. A. Winters, T. C. Merigan, and L. C. Kovari Crystal Structures of a Multidrug-Resistant Human Immunodeficiency Virus Type 1 Protease Reveal an Expanded Active-Site Cavity J. Virol., March 15, 2004; 78(6): 3123 - 3132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Katoh, J. M. Louis, T. Yamazaki, A. M. Gronenborn, D. A. Torchia, and R. Ishima A solution NMR study of the binding kinetics and the internal dynamics of an HIV-1 protease-substrate complex Protein Sci., July 1, 2003; 12(7): 1376 - 1385. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
